Viking Therapeutics said updated data from its Phase 2 obesity program suggest patients who moved from weekly dosing to less frequent regimens can maintain weight control over a 12-week window. The company reported that trial participants mostly kept their weight down after switching dosing schedules, according to the updated dataset. The findings, which could support Viking’s differentiation strategy, come as investors weigh whether GLP-1–class competitors can offer improved convenience without sacrificing efficacy. Viking’s messaging centers on expanding dosing flexibility to reduce injection burden while preserving outcomes. Analysts cited the potential for stronger “competitive positioning,” implying the next readouts and dosing schedule design could matter for future trial plans and partnering interest in the obesity pipeline. The market reaction reflected sensitivity to any evidence of durability with reduced dosing frequency.